



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 209/16, A01N 43/38, A61K 31/40, 31/405	A1	(11) International Publication Number: WO 99/07677 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16333 (22) International Filing Date: 6 August 1998 (06.08.98) (30) Priority Data: 60/054,997 6 August 1997 (06.08.97) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FRITZ, James, Erwin [US/US]; 9757 North Moonstone Place, McCordsville, IN 46055 (US). HIPSKIND, Philip, Arthur [US/US]; 3660 South Farmstone Circle, New Palestine, IN 46163 (US). KALDOR, Stephen, Warren [US/US]; 7435 Burkwood Way, Indianapolis, IN 46254 (US). LOBB, Karen, Lynn [US/US]; 5625 East Lowell Avenue, Indianapolis, IN 46219 (US). NIXON, James, Arthur [US/US]; 7375 Taos Trail, Indianapolis, IN 46219 (US). (74) Agents: GAYLO, Paul, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: 2-ACYLAMINOPROPANAMINES AS TACHYKININ RECEPTOR ANTAGONISTS (57) Abstract Disclosed are non-peptidyl 2-acylaminopropanamine tachykinin receptor antagonists which are useful in the treatment of various conditions including Alzheimer's disease, and pharmaceutical compositions containing such compounds.		